Vasopressor resident survival guide: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 25: | Line 25: | ||
{{Family tree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | |C01= '''Mechanism''' |C02= *Mainly predominant'''α1''' agonist (Vasoconstrictive) <br> *some β1 agonist (↑contractility) |C03= *Mainly predominant '''β1''' agonist (↑contractility) <br> * some α1 agonist(Vasoconstrictive)|C04= *'''V<sub></sub>1''' receptor of GIT vasculatures <br> *Antidiuretic effects |C05= *'''Pure α1''' agonist(Vasoconstrictive) <br> *No β1 |C06= *Mainly predominant '''β1''' agonist (↑contractility) <br> *β2 arterial smooth muscle (Hypotensive) }} | {{Family tree | C01 | | C02 | | C03 | | C04 | | C05 | | C06 | |C01= '''Mechanism''' |C02= *Mainly predominant'''α1''' agonist (Vasoconstrictive) <br> *some β1 agonist (↑contractility) |C03= *Mainly predominant '''β1''' agonist (↑contractility) <br> * some α1 agonist(Vasoconstrictive)|C04= *'''V<sub></sub>1''' receptor of GIT vasculatures <br> *Antidiuretic effects |C05= *'''Pure α1''' agonist(Vasoconstrictive) <br> *No β1 |C06= *Mainly predominant '''β1''' agonist (↑contractility) <br> *β2 arterial smooth muscle (Hypotensive) }} | ||
{{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | {{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | ||
{{Family tree | D01 | | D02 | | D03 | | D04 | | D05 | | D06 | |D01= '''Indication''' |D02= *1st line in : <br> *'''Septic shock''' <br> *'''Cardiogenic shock''' <br>*Undifferentiated shock |D03= 2nd line septic shock |D04= 2nd line septic shock |D05= 1st line '''Neurogenic shock''' <BR> 3rd-4th line septic shock |D06= *1st line '''cardiogenic shock''' <BR>* low output septic shock }} | {{Family tree | D01 | | D02 | | D03 | | D04 | | D05 | | D06 | |D01= '''Indication''' |D02= *'''1st''' line in : <br> *'''Septic shock''' <br> *'''Cardiogenic shock''' <br>*Undifferentiated shock |D03= 2nd line septic shock |D04= 2nd line septic shock |D05= '''1st''' line '''Neurogenic shock''' <BR> 3rd-4th line septic shock |D06= *1st line '''cardiogenic shock''' <BR>* low output septic shock }} | ||
{{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | {{Family tree | | | | | |!| | | |!| | | |!| | | |!| | | |!| | |}} | ||
{{Family tree | E01 | | E02 | | E03 | | E04 | | E05 | | E06 | |E01= '''Dose''' |E02= 1-30 mcg/kg/min |E03= 1-20 mcg/min |E04= 0.03 unit/min |E05= 20-300 mcg/kg/min |E06= 2.5-20 mcg/kg/min }} | {{Family tree | E01 | | E02 | | E03 | | E04 | | E05 | | E06 | |E01= '''Dose''' |E02= 1-30 mcg/kg/min |E03= 1-20 mcg/min |E04= 0.03 unit/min |E05= 20-300 mcg/kg/min |E06= 2.5-20 mcg/kg/min }} | ||
Revision as of 16:24, 6 December 2013
|
Sepsis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Vasopressor resident survival guide On the Web |
|
American Roentgen Ray Society Images of Vasopressor resident survival guide |
|
Risk calculators and risk factors for Vasopressor resident survival guide |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Definition
Causes
Life Threatening Causes
Common Causes
Prognosis
Management
| Vasopressors | |||||||||||||||||||||||||||||||||||||||||||||||||
| Norepinephrine | Dopamine | Vasopressin | Phenylephrine | Dobutamine | |||||||||||||||||||||||||||||||||||||||||||||
| Mechanism | *Mainly predominantα1 agonist (Vasoconstrictive) *some β1 agonist (↑contractility) | *Mainly predominant β1 agonist (↑contractility) * some α1 agonist(Vasoconstrictive) | *V1 receptor of GIT vasculatures *Antidiuretic effects | *Pure α1 agonist(Vasoconstrictive) *No β1 | *Mainly predominant β1 agonist (↑contractility) *β2 arterial smooth muscle (Hypotensive) | ||||||||||||||||||||||||||||||||||||||||||||
| Indication | *1st line in : *Septic shock *Cardiogenic shock *Undifferentiated shock | 2nd line septic shock | 2nd line septic shock | 1st line Neurogenic shock 3rd-4th line septic shock | *1st line cardiogenic shock * low output septic shock | ||||||||||||||||||||||||||||||||||||||||||||
| Dose | 1-30 mcg/kg/min | 1-20 mcg/min | 0.03 unit/min | 20-300 mcg/kg/min | 2.5-20 mcg/kg/min | ||||||||||||||||||||||||||||||||||||||||||||
| Complications | Tachyarrhythmia less than Dopamine (less β1 effect) | Arrhythmia (more β1) | *Coronary spasm *Splanchnic vasoconstriction | Reflex bradycardia (no worsening of tachycardia) (only α1) | Hypotension (β2) | ||||||||||||||||||||||||||||||||||||||||||||
| Cautions | Arrhythmia | *Not in cardiogenic shock *Arrhythmia *Ischemia induced cardiotoxicity | *Ischemic heart *Gut ischemia | *Bradycardia *Heart block | *Hypotension (add α1 agonist) | ||||||||||||||||||||||||||||||||||||||||||||
Do's
- Assess the cause of shock
- Always volume fluid resuscitation first
- Norepinephrine in undifferentiated shock.